[HTML][HTML] Recent advances in the mechanisms and treatment of immune thrombocytopenia
Primary immune thrombocytopenia is an autoimmune disease associated with a reduced
peripheral blood platelet count. The phenotype is variable with some patients suffering no …
peripheral blood platelet count. The phenotype is variable with some patients suffering no …
Eltrombopag added to immunosuppression in severe aplastic anemia
R Peffault de Latour, A Kulasekararaj… - … England Journal of …, 2022 - Mass Medical Soc
Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …
Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia
DJ Kuter, M Efraim, J Mayer, M Trněný… - … England Journal of …, 2022 - Mass Medical Soc
Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …
may increase platelet counts in patients with immune thrombocytopenia by means of dual …
[HTML][HTML] Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review
JL Wautier, MP Wautier - International Journal of Molecular Sciences, 2023 - mdpi.com
Inflammation has been described for two millennia, but cellular aspects and the paradigm
involving different mediators have been identified in the recent century. Two main groups of …
involving different mediators have been identified in the recent century. Two main groups of …
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study
H Al‐Samkari, D Jiang, T Gernsheimer… - British Journal of …, 2022 - Wiley Online Library
Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor
agonist (TPO‐RA) but not another. Limited data are available describing outcomes in …
agonist (TPO‐RA) but not another. Limited data are available describing outcomes in …
A review of romiplostim mechanism of action and clinical applicability
JB Bussel, G Soff, A Balduzzi, N Cooper… - Drug design …, 2021 - Taylor & Francis
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy,
autoimmune disease, bone marrow disorders, pathologic conditions associated with …
autoimmune disease, bone marrow disorders, pathologic conditions associated with …
Reductive metabolism of azo dyes and drugs: Toxicological implications
PD Josephy, E Allen-Vercoe - Food and Chemical Toxicology, 2023 - Elsevier
Azo compounds are widely distributed synthetic chemicals in the modern world. Their most
important applications are as dyes, but, in addition, several azo compounds are used as …
important applications are as dyes, but, in addition, several azo compounds are used as …
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
G Drillet, F Lhomme, S De Guibert, G Manson… - Blood …, 2023 - ashpublications.org
COI notes: GD received honoraria from Janssen. FL received honoraria from Gilead
Sciences, Kite, Roch, and Janssen. SDG received honoraria from Gilead Sciences, AbbVie …
Sciences, Kite, Roch, and Janssen. SDG received honoraria from Gilead Sciences, AbbVie …
[HTML][HTML] Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists
J Gilreath, M Lo, J Bubalo - Drugs, 2021 - Springer
The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag,
and lusutrombopag carry unique US Food and Drug Administration (US FDA)-and European …
and lusutrombopag carry unique US Food and Drug Administration (US FDA)-and European …